再発及び難治性急性骨髄性白血病に対するCytosine Arabinoside中等量療法

抄録

Nine patients with acute myelocytic leukemia, 7 in relapse and 2 refractory to conventional therapy, were treated with intermediate dose cytosine arabinoside (ID Ara-C) in combination with doxorubicin and vincristine.
This schedule consists of 1h infusions of Ara-C in a dose of 500 mg/m² every 12h for 4 days (days 3∼6), in combination with doxorubicin 50 mg/m² on day 1 and vincristine 1 mg/m² on day 2.
In 9 evaluable courses, 5 courses (55.5%) achieved complete remission (CR).
Duration of the CR was 1.5, 2 and 2.6 months. respectively. Other two courses are still in CR (more than 1 and 7.2 months in duration).
Side effects were similar to those in the conventional treatment.
These preliminary data suggest that the therapeutic results of this ID Ara-C regimen are not inferior to comparable schedules with HD Ara-C as reported by others while toxicity is less severe.